These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21823168)

  • 1. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia.
    Suzuki Y; Ono S; Sugai T; Fukui N; Watanabe J; Tsuneyama N; Sawamura K; Someya T
    Hum Psychopharmacol; 2011 Aug; 26(6):440-3. PubMed ID: 21823168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia.
    Suzuki Y; Sugai T; Ono S; Sawamura K; Fukui N; Watanabe J; Tsuneyama N; Saito M; Someya T
    Psychiatry Clin Neurosci; 2014 May; 68(5):353-6. PubMed ID: 24405493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia.
    Tajiri M; Suzuki Y; Sugai T; Tsuneyama N; Someya T
    PLoS One; 2018; 13(7):e0199922. PubMed ID: 30016331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels.
    Mauri MC; Maffini M; Di Pace C; Reggiori A; Paletta S; Moliterno D; Rovera C; Altamura CA
    Int J Psychiatry Clin Pract; 2015 Jun; 19(2):99-105. PubMed ID: 25547438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia.
    Suzuki Y; Sugai T; Fukui N; Watanabe J; Ono S; Tsuneyama N; Saito M; Someya T
    Hum Psychopharmacol; 2013 May; 28(3):215-9. PubMed ID: 23553637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
    Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
    Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
    Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
    Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics.
    Suzuki Y; Sugai T; Fukui N; Watanabe J; Ono S; Tsuneyama N; Saito M; Someya T
    Schizophr Res; 2013 Apr; 145(1-3):116-9. PubMed ID: 23375624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.
    Bushe C; Sniadecki J; Bradley AJ; Poole Hoffmann V
    J Psychopharmacol; 2010 Jul; 24(7):1001-9. PubMed ID: 19240085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.
    Kinon BJ; Volavka J; Stauffer V; Edwards SE; Liu-Seifert H; Chen L; Adams DH; Lindenmayer JP; McEvoy JP; Buckley PF; Lieberman JA; Meltzer HY; Wilson DR; Citrome L
    J Clin Psychopharmacol; 2008 Aug; 28(4):392-400. PubMed ID: 18626265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia.
    Tsuneyama N; Suzuki Y; Sawamura K; Sugai T; Fukui N; Watanabe J; Ono S; Saito M; Someya T
    PLoS One; 2016; 11(3):e0149518. PubMed ID: 26930407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome and olanzapine plasma levels in acute schizophrenia.
    Mauri MC; Steinhilber CP; Marino R; Invernizzi E; Fiorentini A; Cerveri G; Baldi ML; Barale F
    Eur Psychiatry; 2005 Jan; 20(1):55-60. PubMed ID: 15642445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
    Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
    J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia.
    Lu ML; Chen CH; Kuo PT; Lin CH; Wu TH
    Schizophr Res; 2018 Mar; 193():139-145. PubMed ID: 28720417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
    Crawford AM; Beasley CM; Tollefson GD
    Schizophr Res; 1997 Jul; 26(1):41-54. PubMed ID: 9376336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
    Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia.
    Lu ML; Wu YX; Chen CH; Kuo PT; Chen YH; Lin CH; Wu TH
    PLoS One; 2016; 11(2):e0148539. PubMed ID: 26849777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
    Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
    J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.